WeVote
Log In

Bill

Bill

HB 3454

Allow school board members to run for the state legislature

2025 Regular Session Introduced by Bill Ridenour

Modernizes statutes to use FDA-approved epinephrine delivery devices (not just auto-injectors), expands officer training and agency policies, preserving good-faith immunity.

To House Education
#elections
0
WeVote Research Nonpartisan
Bill Summary · HB 3454

Summary — HB 3454 (104th General Assembly, 2025–2026)

Note on title discrepancy: The bill file lists the title as “Relating to the provision of adoption information to students,” but the text of HB 3454 as introduced amends multiple statutes to replace references to “epinephrine auto‑injector” (or “epinephrine injector”) with “FDA approved epinephrine delivery device or product” and renames the Epinephrine Injector Act accordingly. This summary describes the substance of the bill as drafted (epinephrine device terminology and related provisions), not the unrelated title.

Purpose and intent

Modernize statutory language to encompass any FDA‑approved epinephrine delivery device or product (not solely branded or traditional “auto‑injectors”), and update related training, policy, procurement, and liability provisions across multiple Illinois statutes and agencies.

Key provisions

  • Replaces the terms “epinephrine auto‑injector” and “epinephrine injector” with “FDA approved epinephrine delivery device or product” throughout multiple Acts.
  • Changes the name of the Epinephrine Injector Act to the “FDA Approved Epinephrine Delivery Device or Product Act.”
  • Updates training and authorization language in:
    • Illinois State Police Act (20 ILCS 2610/40) and
    • Illinois Police Training Act (50 ILCS 705/10.19) — to allow the Illinois State Police and local law enforcement to train officers to recognize and respond to anaphylaxis and to carry, administer, or assist with FDA‑approved epinephrine devices while on duty.
  • Specifies training content: recognizing allergic reaction symptoms, emergency response, how to administer the device/product, response to known and unknown allergies, and a competency test.
  • Requires agencies that authorize carrying/administration to adopt written policies governing acquisition, storage, transportation, administration, and disposal.
  • Permits physicians, PAs with prescriptive authority, or APRNs with prescriptive authority to provide standing protocols or prescriptions for agencies to maintain devices for use.
  • Retains civil immunity for officials, agencies, and providers acting in good faith when administering the device; removes protection only for willful & wanton conduct.

Statutes amended (selected)

Bill text cites amendments to: 20 ILCS 2610/40; 50 ILCS 705/10.19; 105 ILCS 5/22‑30 (School Code, truncated in text); 215 ILCS 5/356z.33; 225 ILCS 60/65; 410 ILCS 27/1, /5, /10, /15, /20; 410 ILCS 607/10; 410 ILCS 620/3.21; 410 ILCS 642/20 — i.e., multiple public safety, education, insurance, and health‑related provisions.

Who is affected

  • Illinois State Police and local law enforcement agencies and officers (training, procurement, deployment).
  • Health care prescribers who issue standing orders/protocols for agencies.
  • Agencies and institutions required to adopt policies (including likely schools, given School Code amendments).
  • Individuals experiencing anaphylaxis who may receive FDA‑approved epinephrine devices from officers or agencies.
  • Potential procurement and training budgets at agency level.

Procedural status

  • Introduced by Rep. Joyce Mason (filed Feb 2025; introduced Feb 18/27, 2025).
  • Referred to multiple committees (Education; Prescription Drug Affordability & Accessibility; Insurance; Rules).
  • Co‑sponsors: Harry Benton, Dagmara Avelar, Camille Y. Lilly, Jawaharial Williams.
  • Legislative actions through June 28, 2025: read, committee referrals, added co‑sponsors; currently “in committee upon adjournment” (6/28/2025).

Potential impacts and considerations

  • Modernizes statutory language to include future or alternative FDA‑approved epinephrine delivery technologies (e.g., prefilled syringes or emerging devices), reducing ambiguity about permitted products.
  • Requires agencies to update policies, training curricula, procurement and disposal procedures — with modest administrative and potential equipment costs.
  • Maintains civil immunity for good‑faith emergency administration, preserving legal protections for first responders and prescribing clinicians, while excluding willful/wanton conduct.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.